Pacific Shuanglin Bio-pharmacy Co., LTD (SHE:000403)
China
· Delayed Price · Currency is CNY 21.82
-0.17 (-0.77%)
May 13, 2025, 3:04 PM CST
SHE:000403 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 | 2015 - 2019 |
| Operating Revenue | 2,593 | 2,654 | 2,325 | 2,396 | 1,966 | 1,042 | Upgrade
|
| Other Revenue | 1.05 | 1.05 | 3.27 | 9.59 | 5.27 | 7.44 | Upgrade
|
| Revenue | 2,594 | 2,655 | 2,329 | 2,405 | 1,972 | 1,050 | Upgrade
|
| Revenue Growth (YoY) | 3.60% | 14.00% | -3.18% | 21.98% | 87.80% | 14.67% | Upgrade
|
| Cost of Revenue | 1,335 | 1,352 | 1,130 | 1,151 | 1,064 | 537.36 | Upgrade
|
| Gross Profit | 1,259 | 1,303 | 1,199 | 1,254 | 907.93 | 512.58 | Upgrade
|
| Selling, General & Admin | 441.08 | 437.26 | 465.81 | 565.05 | 419 | 276.16 | Upgrade
|
| Research & Development | 44.44 | 55.18 | 79.69 | 75.36 | 35.63 | 11 | Upgrade
|
| Other Operating Expenses | 26.21 | 22.07 | 21.69 | 16.8 | 15.28 | 2.52 | Upgrade
|
| Operating Expenses | 502.79 | 509.9 | 565.15 | 666.86 | 477.73 | 285.99 | Upgrade
|
| Operating Income | 756.3 | 793.13 | 633.7 | 587.01 | 430.2 | 226.59 | Upgrade
|
| Interest Expense | -12.19 | -10.67 | -9.63 | -12.03 | -10.78 | -19.31 | Upgrade
|
| Interest & Investment Income | 73.32 | 78.01 | 75.08 | 68.22 | 62.3 | 18.31 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.13 | 0.13 | -0.12 | 2.4 | -0.21 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 8.36 | 0.03 | 0.64 | -2.23 | -3.44 | -3.67 | Upgrade
|
| EBT Excluding Unusual Items | 825.92 | 860.61 | 699.67 | 643.37 | 478.06 | 221.92 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -103.18 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.26 | 6.38 | -18.97 | 4.93 | 74.21 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.7 | -0.12 | -0.54 | 0.44 | 0.27 | 0.02 | Upgrade
|
| Asset Writedown | -3.46 | -3.46 | -1.29 | -3.59 | -0.49 | -5.27 | Upgrade
|
| Legal Settlements | - | - | - | - | -2.14 | - | Upgrade
|
| Other Unusual Items | -15.06 | -10.87 | 9.25 | 15.24 | 11.28 | 0.52 | Upgrade
|
| Pretax Income | 815.19 | 852.78 | 688.11 | 660.39 | 458.01 | 217.19 | Upgrade
|
| Income Tax Expense | 103.08 | 107.74 | 76.64 | 72.7 | 66.47 | 34.51 | Upgrade
|
| Earnings From Continuing Operations | 712.11 | 745.04 | 611.47 | 587.69 | 391.54 | 182.68 | Upgrade
|
| Minority Interest in Earnings | 0.35 | 0.28 | 0.64 | -0.56 | -0.48 | 3.28 | Upgrade
|
| Net Income | 712.46 | 745.32 | 612.11 | 587.13 | 391.06 | 185.97 | Upgrade
|
| Net Income to Common | 712.46 | 745.32 | 612.11 | 587.13 | 391.06 | 185.97 | Upgrade
|
| Net Income Growth | 5.13% | 21.76% | 4.25% | 50.14% | 110.29% | 15.90% | Upgrade
|
| Shares Outstanding (Basic) | 737 | 731 | 729 | 731 | 706 | 490 | Upgrade
|
| Shares Outstanding (Diluted) | 737 | 731 | 729 | 731 | 707 | 490 | Upgrade
|
| Shares Change (YoY) | 1.62% | 0.27% | -0.31% | 3.37% | 44.24% | 0.23% | Upgrade
|
| EPS (Basic) | 0.97 | 1.02 | 0.84 | 0.80 | 0.55 | 0.38 | Upgrade
|
| EPS (Diluted) | 0.97 | 1.02 | 0.84 | 0.80 | 0.55 | 0.38 | Upgrade
|
| EPS Growth | 3.46% | 21.43% | 4.58% | 45.24% | 45.80% | 15.64% | Upgrade
|
| Free Cash Flow | -245.84 | -198.92 | 301.74 | 145.58 | 82.06 | 154.66 | Upgrade
|
| Free Cash Flow Per Share | -0.33 | -0.27 | 0.41 | 0.20 | 0.12 | 0.32 | Upgrade
|
| Dividend Per Share | 0.500 | 0.500 | 0.200 | 0.080 | 0.056 | - | Upgrade
|
| Dividend Growth | 150.00% | 150.00% | 149.33% | 43.24% | - | - | Upgrade
|
| Gross Margin | 48.54% | 49.08% | 51.48% | 52.13% | 46.05% | 48.82% | Upgrade
|
| Operating Margin | 29.16% | 29.88% | 27.21% | 24.41% | 21.82% | 21.58% | Upgrade
|
| Profit Margin | 27.47% | 28.08% | 26.28% | 24.41% | 19.83% | 17.71% | Upgrade
|
| Free Cash Flow Margin | -9.48% | -7.49% | 12.96% | 6.05% | 4.16% | 14.73% | Upgrade
|
| EBITDA | 873.05 | 913.93 | 770.71 | 704.63 | 538.01 | 273.96 | Upgrade
|
| EBITDA Margin | 33.66% | 34.43% | 33.10% | 29.30% | 27.29% | 26.09% | Upgrade
|
| D&A For EBITDA | 116.75 | 120.8 | 137.02 | 117.62 | 107.82 | 47.37 | Upgrade
|
| EBIT | 756.3 | 793.13 | 633.7 | 587.01 | 430.2 | 226.59 | Upgrade
|
| EBIT Margin | 29.16% | 29.88% | 27.21% | 24.41% | 21.82% | 21.58% | Upgrade
|
| Effective Tax Rate | 12.65% | 12.63% | 11.14% | 11.01% | 14.51% | 15.89% | Upgrade
|
| Revenue as Reported | 2,594 | 2,655 | 2,329 | 2,405 | 1,972 | 1,050 | Upgrade
|
Updated Oct 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.